

To,

Dated: 17/05/2021

The Manager – Listing Department
National Stock exchange of India Limited
Exchange Plaza 5th Floor
Plot No C/1, G, Block,
Bandra Kurla Complex , bandra (E)
Mumbai-400 051

Subject: Intimation of Acquisition of Company pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

With reference to the company “INNOVANA THINKLABS LIMITED” has entered into tie up with “LAXO MEDICARE PRIVATE LIMITED” by subscribing 3590 Equity share of Rs 10 /-each at a premium of Rs 5562 /- per equity share resulted into 26.42% shareholding in the said Company.

The Details are attached in Annexure A

You are requested to kindly take the same on record.

Thanking You

For Innovana Thinklabs Limited

Sd/-

Vasu Ajay Anand
Company Secretary and Compliance officer



Plot No. D-41, Patrakar Colony, Near
Jawahar Nagar ,Moti Dungri Vistar Yojna,
Raja Park, Jaipur - 302004 (Raj), INDIA



www.innovanathinklabs.com
info@innovanathinklabs.com



+91-141-4919128
+91-141-4919129

Acquisition Details

Annexure –A

S.no	Details of Events that need to be provided	Information of such events
a.	Name of the Target entity, details in brief such as size, turnover etc.	<p>LAXO MEDICARE PRIVATE LIMITED (as on March 2020)</p> <p>A) Authorized Capital Rs.100,000/- divided into 10,000 equity shares having face value of Rs. 10/- each.</p> <p>B) Paid up capital Rs. 100,000/- divided into 10,000 equity shares having face value of Rs. 10/- each.</p> <p>C) Turnover of financial year March 2020-99,97,181.53/-</p>
b.	<p>Whether the acquisition would fall within related party transaction (s) and whether the promoter/ Promoter group companies have any interest in the entity being acquired?</p> <p>If yes, nature of interest and details thereof and whether the same is done at 'arm length'</p>	NO
c.	Industry to which the entity being acquired belongs	Pharmaceutical Industry
d.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the Company) ;	Enchantment of the interest in the Pharmaceutical industry and Equipment.



Plot No. D-41, Patrakar Colony, Near
Jawahar Nagar ,Moti Dungri Vistar Yojna,
Raja Park, Jaipur - 302004 (Raj), INDIA



www.innovanathinklabs.com
info@innovanathinklabs.com



+91-141-4919128
+91-141-4919129

e.	Brief details of any governmental or regulatory approvals required for the acquisition	No regulatory approvals are required for this acquisition.
f.	Indicative time period for completion of the acquisition	N.A
g.	Nature of consideration – whether cash consideration or share swap and details of the share	Cash Consideration
h.	Cost of acquisition or price at which the share are required	3590 Equity share of Rs. 10 Each at premium of Rs 5562 /- per equity share
i.	Percentage of shareholding/ control acquired and / or number of share acquired	The Company acquired control of 26.42% by subscribing 3590 equity share of Rs. 10 each premium of Rs. 5562/- per equity share.
j.	Brief background about the entity acquired in terms products/ (In brief)	<p>India's pharmaceutical industry has emerged as world's third largest producer of drugs in terms of volume.</p> <p>Laxo Medicare is an ethical pharmaceutical start-up company engages in prescription drug marketing. These drugs are licensed drugs that are regulated by various legislations to require a written medical prescription before medicine procured. Laxo develops markets and modern branded pharmaceutical products.</p> <p>Laxo products have the hallmark of technology-based differentiation and cover the full range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams and liquids.</p>



Plot No. D-41, Patrakar Colony, Near
Jawahar Nagar ,Moti Dungri Vistar Yojna,
Raja Park, Jaipur - 302004 (Raj), INDIA



www.innovanathinklabs.com
info@innovanathinklabs.com



+91-141-4919128
+91-141-4919129